| Intensity Modulated Radiation Therapy Policy, Professional | Commercial | — | Original policy ↗ |
| Intensity-Modulated Radiation Therapy | 2026T0407HH · Effective Mar 1, 2026 · Commercial | 8 | Original policy ↗ |
| Interspinous Fusion and Decompression Devices – Commercial and Individual Exchange Medical Policy | 2026T0638H · Commercial | 8 | Original policy ↗ |
| Intestinal Dysbiosis and Fecal Microbiota Transplant Testing Policy, Professional and Facility | 2026R8002A · Effective Aug 26, 2026 · Commercial | 12 | Original policy ↗ |
| Intracanalicular and Intravitreal Corticosteroid Implants | 2026D0107H · Effective Aug 1, 2026 · Commercial | 4 | Original policy ↗ |
| Intracellular Micronutrient Analysis Policy, Professional and Facility | 2026R8010A · Effective Aug 26, 2026 · Commercial | 24 | Original policy ↗ |
| Intraoperative Neuromonitoring Policy, Professional | Commercial | 31 | Original policy ↗ |
| Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease | 2026D0048Q · Effective Jun 1, 2026 · Commercial | 3 | Original policy ↗ |
| Intravenous Iron Replacement Therapy (Injectafer® & Monoferric®) | 2026D0088R · Effective Sep 1, 2026 · Commercial | 2 | Original policy ↗ |
| Iron Homeostasis and Metabolism Policy, Professional and Facility | 2026R8001A · Effective Aug 26, 2026 · Commercial | 2 | Original policy ↗ |
| Itvisma® (Onasemnogene Abeparvovec-Brve) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026D0142C · Effective Oct 1, 2026 · Commercial | 1 | Original policy ↗ |
| Joint Procedures | MMP052.14 · Effective Oct 1, 2026 | 52 | Original policy ↗ |
| Kebilidi® (Eladocagene Exuparvovec-Tneq) | 2026D0136B · Effective Aug 1, 2026 · Commercial | 2 | Original policy ↗ |
| Ketalar® (Ketamine) and Spravato® (Esketamine) | 2026D0069Q · Effective May 1, 2026 · Commercial | 2 | Original policy ↗ |
| Kisunla™ (Donanemab-Azbt) – Commercial Medical Benefit Drug Policy | 2026D0130D · Effective Feb 1, 2026 · Commercial | 1 | Original policy ↗ |
| Korsuva® (Difelikefalin) | 2026D0115F · Effective Jul 1, 2026 · Commercial | 1 | Original policy ↗ |
| Krystexxa® (Pegloticase) | 2025D0082H · Effective Nov 1, 2025 · Commercial | 1 | Original policy ↗ |
| Laboratory Services Policy, Professional | 2026R0010C · Commercial | 74 | Original policy ↗ |
| Lemtrada® (Alemtuzumab) | 2026D0023Z · Effective Apr 1, 2026 · Commercial | 1 | Original policy ↗ |
| Leqembi® (Lecanemab-Irmb) | 2026D0125E · Effective Apr 1, 2026 · Commercial | 1 | Original policy ↗ |
| Leqvio® (Inclisiran) | 2026D0101L · Effective Jun 1, 2026 · Commercial | 1 | Original policy ↗ |
| Light and Laser Therapy – Commercial and Individual Exchange Medical Policy | 2026T0337GG · Commercial | 6 | Original policy ↗ |
| Liposuction for Lipedema | 2026T0625K · Effective Jan 1, 2026 · Commercial | 3 | Original policy ↗ |
| Long-Acting Injectable Antiretroviral Agents for HIV | 2026D0103O · Effective Oct 1, 2026 · Commercial | 4 | Original policy ↗ |
| Lower Extremity Endovascular Procedures | 2026T0602T · Effective Oct 1, 2026 · Commercial | 48 | Original policy ↗ |
| Lower Extremity Prosthetics | 2026T0645N · Effective Aug 1, 2026 · Commercial | 200 | Original policy ↗ |
| Lumvoa™ (Veligrotug-Vvze) and Tepezza® (Teprotumumab-Trbw) | 2026D0089M · Effective Oct 1, 2026 · Commercial | 3 | Original policy ↗ |
| Luxturna® (Voretigene Neparvovec-Rzyl) | 2026D0063L · Effective Oct 1, 2026 · Commercial | 1 | Original policy ↗ |
| Lyme Disease Testing Policy, Professional and Facility | 2026R8012A · Effective Aug 26, 2026 · Commercial | 6 | Original policy ↗ |
| Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) Scan – Site of Service | MP.13.20 · Effective Sep 1, 2026 · Commercial | 122 | Original policy ↗ |
| Manipulation Under Anesthesia | 2026T0515CC · Effective Feb 1, 2026 · Commercial | 10 | Original policy ↗ |
| Manipulative Therapy | 2026T0541X · Effective Jun 1, 2026 · Commercial | 11 | Original policy ↗ |
| Maximum Dosage and Frequency | 2026D0034AV · Effective Oct 1, 2026 · Commercial | 121 | Original policy ↗ |
| Maximum Frequency Per Day Policy, Professional | Commercial | 7 | Original policy ↗ |
| Mechanical Stretching Devices | 2026T0481BB · Effective Jan 1, 2026 · Commercial | 26 | Original policy ↗ |
| Medical Benefit Therapeutic Equivalent Medications – Excluded Drugs | 2026D0113E · Effective Oct 1, 2026 · Commercial | — | Original policy ↗ |
| Medical Policy Update Bulletin Archives | | — | Original policy ↗ |
| Medical Records Documentation Used for Reviews | Effective Oct 1, 2026 · Commercial | 4 | Original policy ↗ |
| Medical Therapies for Enzyme Deficiencies | 2026D0052AF · Effective Oct 1, 2026 · Commercial | 16 | Original policy ↗ |
| Medicare Advantage Medical Policy Update Bulletin: August 2026 | Effective Aug 1, 2026 | — | Original policy ↗ |
| Medicare Advantage Medical Policy Update Bulletin: October 2026 | Effective Oct 1, 2026 | — | Original policy ↗ |
| Medicare Advantage Medical Policy Update Bulletin: September 2026 | | — | Original policy ↗ |
| Medicare Part B Step Therapy Programs | IAP.001.31 · Effective Oct 1, 2026 | 211 | Original policy ↗ |
| Medications/Drugs (Outpatient/Part B) | MMP057.57 · Effective Oct 1, 2026 | 2 | Original policy ↗ |
| Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases | 2026T0322MM · Effective Aug 1, 2026 · Commercial | 14 | Original policy ↗ |
| Minimally Invasive Spine Surgery Procedures | 2026T0640H · Effective Feb 1, 2026 · Commercial | 10 | Original policy ↗ |
| Modifier Policy, Facility | Commercial | — | Original policy ↗ |
| Modifier SU Policy, Professional | Effective Jun 28, 2026 · Commercial | — | Original policy ↗ |
| Mohs Micrographic Surgery Policy, Professional | Commercial | 15 | Original policy ↗ |
| Molecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions | 2026T0652H · Effective Aug 1, 2026 · Commercial | 22 | Original policy ↗ |
